Why GLP-1 Non-Responders Need Earlier Anti-Obesity Medication Intervention Introduction GLP-1 non-responders represent a critical challenge in obesity management that requires prompt medical intervention. Despite the availability of six FDA-approved anti-obesity medications (AOMs) for chronic weight management, current guidelines recommend waiting six months after behavioral therapy
Tag: #MetabolicHealth
